Earning Date, Transcript Summary & Report

Revenue Growth Momentum: Fennec Pharmaceuticals reported a 40% growth in revenues over the past 12 months, indicating strong business momentum.

Quarterly Net Product Sales: The company achieved $7.9 million in net product sales for Q4 2024, reflecting a quarterly growth rate of approximately 13%.

Net Product Sales Growth: For the full fiscal year 2024, net product sales reached $29.6 million, up from $21.3 million in 2023, showcasing significant year-over-year growth.

Cash Burn Management: Fennec managed to limit cash burn to approximately $0.6 million in Q4 2024, demonstrating operational efficiency during a period of change.

PEDMARK Integration Success: The company has successfully integrated PEDMARK into treatment plans at major academic centers, validating its clinical utility and expanding patient access.

PEDMARK Adoption in AYA Segment: Fennec's PEDMARK is gaining traction in the adolescent and young adult (AYA) segment, with an estimated 20,000 cisplatin chemotherapy patients treated annually in the U.S.

NCCN Endorsement Impact: The endorsement of PEDMARK by the National Comprehensive Cancer Network (NCCN) with a 2A recommendation enhances its credibility and market acceptance.

Exclusive Licensing Agreement: Fennec has executed an exclusive licensing agreement with Norgine for PEDMARQSI, which has been launched in Germany and the U.K., creating new revenue streams.

Projected Net Sales Growth: The company anticipates significant growth in net product sales in the second half of 2025 as foundational initiatives take effect.

Cash Position Improvement: Fennec's cash position improved, with $26.6 million in cash and cash equivalents as of December 31, 2024, bolstered by proceeds from the Norgine transaction.

Earnings Miss Report: Fennec Pharmaceuticals Inc. missed earnings expectations with a reported EPS of $-0.06, while expectations were $0.56.

Cash Burn Challenges: The company reported a cash burn of approximately $0.6 million in Q4 2024, indicating ongoing financial challenges despite revenue growth.

Increased Marketing Expenses: Selling and marketing expenses increased significantly to $18.4 million for the fiscal year 2024, up from $12.1 million in 2023, raising concerns about cost management.

Increased Administrative Expenses: General and administrative expenses increased by $2.4 million compared to fiscal year 2023, primarily due to European pre-commercialization expenses and costs associated with the Norgine transaction.

Cash Operating Expenses Outlook: The company anticipates cash operating expenses to remain similar in 2025, which may hinder profitability and financial flexibility.

Revenue vs. Operational Costs: Despite a 40% revenue growth, the company still reported a net product sales of $29.6 million for the full fiscal year 2024, which may not be sufficient to cover increasing operational costs.